Highly Efficient and Selective Inhibitors Targeting BET Bromodomains
BET proteins are important because they regulate both normal transcription processes as well as the transcription of oncogenes such as c-myc and Bcl-2 in various types of cancer. An efficient and selective inhibition of the BET proteins is therefore of great importance for cancer therapies. Various compounds, including benzenesulfonamide derivates are known to possess this property. However, there is a great desire for further, more selective inhibitors.
The use of sulfoximine, sulfondiimide and sulfonimidamide derivatives allows to generate novel molecules with a stereogenic sulfur atom. The utilization of this chirality provides new, highly effective and selective BET inhibitors.
- Novel BET inhibitors bearing a stereocenter
- Chirality is the key to high efficacy and selectivity
- Patent application at the German Patent and Trade Mark Office. The patent application pending is not yet published in the Patent Gazette. Only after the first publication of the patent application, the applicant can derive rights therefrom and can especially claim compensation from third parties.
- Proof of concept and Ongoing research
- RWTH Aachen University is looking for partners for patent exploitation.
Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Maligncies
B. Altenburg, M. Frings, J.-H. Schöbel, J. Goßen, K. Pannen, K. Vanderliek, G. Rossetti, S. Koschmieder, N. Chatain, C. Bolm, ACS Med. Chem. Lett. 2020, here.
RWTH Technology #2252
Fields of application Pharmaceutical Development; Oncology
Keywords #BETinhibitor #Sulfoximines #Sulfondiimides #Sulfonimidamides